Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

BACKGROUND: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Moon, Jai-Hee, Hong, Seung-Woo, Kim, Jeong Eun, Shin, Jae-Sik, Kim, Jin-Sun, Jung, Soo-A, Ha, Seung Hee, Lee, Seul, Kim, Joseph, Lee, Dae Hee, Park, Yoon Sun, Kim, Dong Min, Park, Sang-Soo, Hong, Jun Ki, Kim, Do Yeon, Kim, Eun Ho, Jung, Joonyee, Kim, Mi Jin, Kim, Seung-Mi, Deming, Dustin A., Kim, Kyunggon, Kim, Tae Won, Jin, Dong-Hoon
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://ncbi.nlm.nih.gov/pubmed/30944457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0434-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares